Patents by Inventor Elana S. Erhlich

Elana S. Erhlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VIF AS A TARGET FOR HIV INHIBITION
    Publication number: 20140057948
    Abstract: The present invention relates, e.g., to a method for inhibiting infectivity of a lentivirus (e.g., a lentivirus which expresses a Viral infectivity factor (Vif) protein), such as, e.g., SIV, SHIV and/or HIV, comprising contacting a cell which is producing the virus with an antiviral-effective amount of a membrane-permeable Zinc (Zn) chelator, wherein the antiviral-effective amount of the Zn chelator does not substantially inhibit proteins in the cell which contain Zn-binding motifs other than lentivirus Vif. Kits and pharmaceutical compositions are also disclosed, as is a method for identifying inhibitors of lentiviruses that target a specific zinc-binding motif of the lentivirus Vif protein.
    Type: Application
    Filed: December 11, 2012
    Publication date: February 27, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Xiao-Fang Yu, Elana S. Erhlich, Xiao Zuoxiang
  • Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
    Patent number: 8338089
    Abstract: The present invention relates, e.g., to a method for inhibiting infectivity of a lentivirus (e.g., a lentivirus which expresses a Viral infectivity factor (Vif) protein), such as, e.g., SIV, SHIV and/or HIV, comprising contacting a cell which is producing the virus with an antiviral-effective amount of a membrane-permeable Zinc (Zn) chelator, wherein the antiviral-effective amount of the Zn chelator does not substantially inhibit proteins in the cell which contain Zn-binding motifs other than lentivirus Vif. Kits and pharmaceutical compositions are also disclosed, as is a method for identifying inhibitors of lentiviruses that target a specific zinc-binding motif of the lentivirus Vif protein.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: December 25, 2012
    Assignee: The Johns Hopkins University
    Inventors: Xiao-Fang Yu, Elana S. Erhlich, Xiao Zuoxiang
  • VIF as a traget for HIV inhibition
    Publication number: 20080206357
    Abstract: The present invention relates, e.g., to a method for inhibiting infectivity of a lentivirus (e.g., a lentivirus which expresses a Viral infectivity factor (Vif) protein), such as, e.g., SIV, SHIV and/or HIV, comprising contacting a cell which is producing the virus with an antiviral-effective amount of a membrane-permeable Zinc (Zn) chelator, wherein the antiviral-effective amount of the Zn chelator does not substantially inhibit proteins in the cell which contain Zn-binding motifs other than lentivirus Vif. Kits and pharmaceutical compositions are also disclosed, as is a method for identifying inhibitors of lentiviruses that target a specific zinc-binding motif of the lentivirus Vif protein.
    Type: Application
    Filed: November 20, 2007
    Publication date: August 28, 2008
    Inventors: Xiao-Fang Yu, Elana S. Erhlich, Xiao Zuoxiang